EMA Recommends Granting a Marketing Authorisation for Generic Trabectedin By Ogkologos - April 30, 2025 87 0 Facebook Twitter Google+ Pinterest WhatsApp Trabectedin Accord is a generic of Yondelis, which has been authorised in the EU since 2007 Source RELATED ARTICLESMORE FROM AUTHOR Adding Retifanlimab To First-Line Chemotherapy for Patients with Advanced Squamous Cell Anal Cancer Adding Lurbinectedin to First-Line Atezolizumab Maintenance Treatment Prolongs Survival Over Atezolizumab Alone in Patients with ES-SCLC FDA Grants Accelerated Approval to Datopotamab Deruxtecan-dlnk for EGFR-mutated Non-Small Cell Lung Cancer MOST POPULAR Opinion: ‘We’re making headway, but we can’t be complacent’ February 11, 2021 FDA Approves Vorasidenib for Grade 2 Astrocytoma or Oligodendroglioma with a... August 29, 2024 This Amazing Woman Can Smell Alzheimer’s, Parkinson’s, and Cancer Years Before... March 22, 2019 Young Mom-of-Three Learns She Has Stage 4 Breast Cancer, 5 Days... January 4, 2021 Load more HOT NEWS Evaluating Targeted Therapy for People With Advanced Gastric or Gastroesophageal Junction... No Survival Benefit from Adding Preoperative Chemoradiotherapy to Perioperative Chemotherapy in... Opinion: “We’ve been pushing for change for 20 years. We’re not... Neoadjuvant Pembrolizumab Associated with Limited Side Effects and High Clinical Activity...
